Real World Safety and Outcome of First Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study) DOI Open Access
Alessandro Cafaro, Flavia Foca, Oriana Nanni

и другие.

Опубликована: Апрель 16, 2024

Results from the phase III Keynote-024 clinical trial have established Pembrolizumab monotherapy as first-line standard of care for patients with metastatic NSCLC who PD-L1 expression ≥ 50%, EGFR and ALK wild-type. However, given differences between treated in routine practice within a trial, real-world data are needed to confirm treatment benefit practice. Given lack on large cohorts long follow-up, we designed retrospective observational study were Pembrolizumab, starting its reimbursement eligibility until December 2020. The primary endpoints assess PFS OS using Kaplan-Meier method, response safety. We followed 880 (median follow-up: 35.1 months) February 2022. Median 8.6 months (95% CI: 7.6-10.0) 25.5 21.8-31.6), respectively. also found that ECOG PS, smoking habit prognostic factors PFS, while age, sex, histology had an impact OS. Multivariable analysis confirms role both 39.9% reported adverse event, but only 6.3% discontinued therapy due toxicity. Our results suggest long-term setting well safety profile consistent Keynote-042. Many collected variables appear influence outcome, these exploratory unadjusted analyses should be interpreted caution.

Язык: Английский

Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study) DOI Open Access
Alessandro Cafaro, Flavia Foca, Oriana Nanni

и другие.

Cancers, Год журнала: 2024, Номер 16(10), С. 1802 - 1802

Опубликована: Май 8, 2024

Results from the phase III Keynote-024 clinical trial established pembrolizumab monotherapy as first-line standard of care for patients with metastatic NSCLC who have PD-L1 expression ≥ 50%, EGFR, and ALK wild-type tumors. However, given differences between treated in routine practice those a trial, real-world data are needed to confirm treatment benefit practice. Given lack on large cohorts long follow-ups, we designed an observational retrospective study were pembrolizumab, starting its reimbursement eligibility until December 2020. The primary endpoints PFS OS, determined using Kaplan–Meier method. Response safety also evaluated. We followed 880 (median follow-up: 35.1 months) February 2022. Median OS 8.6 months (95% CI: 7.6–10.0) 25.5 21.8–31.6), respectively. found that ECOG PS, expression, habitual smoking prognostic factors PFS, while age, sex, histology had impact OS. Multivariable analysis confirms role both 39.9% reported adverse event, but only 6.3% discontinued therapy due toxicity. Our results suggest long-term setting, well profile consistent Keynote-024. Many collected variables appear influence outcome, these exploratory unadjusted analyses should be interpreted caution.

Язык: Английский

Процитировано

4
Identification of cancer cell-intrinsic biomarkers associated with tumor progression and characterization of SFTA3 as a tumor suppressor in lung adenocarcinomas DOI Creative Commons
Yu Zhao, Chengcheng Zhou, Ling Zuo

и другие.

BMC Cancer, Год журнала: 2025, Номер 25(1)

Опубликована: Янв. 8, 2025

Recent advancements in contemporary therapeutic approaches have increased the survival rates of lung cancer patients; however, long-term benefits remain constrained, underscoring pressing need for novel biomarkers. Surfactant-associated 3 (SFTA3), a long non-coding RNA predominantly expressed normal epithelial cells, plays crucial role development. Nevertheless, its function adenocarcinoma (LUAD) remains inadequately understood. Single-cell sequencing data were utilized to identify cell-intrinsic gene signatures associated with progression LUAD, and their roles LUAD comprehensively analyzed. Serum samples collected quantify expression levels SFTA3 patients. Furthermore, series biological experiments, including cell viability assays, scratch wound healing colony formation conducted demonstrate tumor-suppressive effects SFTA3. was performed elucidate molecular mechanisms underlying cells. We constructed prognostic model comprising eight genes: ALDOA, ATP5MD, SERPINH1, SFTA3, SLK, U2SURP, SCGB1A1, SCGB1A3. The effectively stratified patients into high- low-risk categories, revealing that experienced superior clinical outcomes, exhibited an immunologically hot tumor microenvironment (TME), had greater probability responding immunotherapy. In contrast, high-risk group cold TME may benefit more from chemotherapy. our study revealed progressive decrease cells correlated advancement. Notably, serum significantly decreased suggesting potential utility liquid biopsy diagnosis. Additionally, knockdown enhances proliferation migration whereas overexpression inhibits these phenotypes. epithelial-mesenchymal transition pathway enriched following silencing, impact by modulating this process. also identified key transcription factors epigenetic implicated downregulation LUAD. developed robust as biomarker applications diagnosis, prognosis, personalized treatment findings offer new insights tumorigenesis immune evasion.

Язык: Английский

Процитировано

0
Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysis DOI Creative Commons
Jiacheng Yao, Sihan Li, Lu Bai

и другие.

EClinicalMedicine, Год журнала: 2025, Номер 81, С. 103081 - 103081

Опубликована: Янв. 31, 2025

Язык: Английский

Процитировано

0
Real World Safety and Outcome of First Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study) DOI Open Access
Alessandro Cafaro, Flavia Foca, Oriana Nanni

и другие.

Опубликована: Апрель 16, 2024

Results from the phase III Keynote-024 clinical trial have established Pembrolizumab monotherapy as first-line standard of care for patients with metastatic NSCLC who PD-L1 expression ≥ 50%, EGFR and ALK wild-type. However, given differences between treated in routine practice within a trial, real-world data are needed to confirm treatment benefit practice. Given lack on large cohorts long follow-up, we designed retrospective observational study were Pembrolizumab, starting its reimbursement eligibility until December 2020. The primary endpoints assess PFS OS using Kaplan-Meier method, response safety. We followed 880 (median follow-up: 35.1 months) February 2022. Median 8.6 months (95% CI: 7.6-10.0) 25.5 21.8-31.6), respectively. also found that ECOG PS, smoking habit prognostic factors PFS, while age, sex, histology had an impact OS. Multivariable analysis confirms role both 39.9% reported adverse event, but only 6.3% discontinued therapy due toxicity. Our results suggest long-term setting well safety profile consistent Keynote-042. Many collected variables appear influence outcome, these exploratory unadjusted analyses should be interpreted caution.

Язык: Английский

Процитировано

2